Live feed02:00:00·61dPRReleasevia QuantisnowTakeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia VeraByQuantisnow·Wall Street's wire, on your screen.PTGX· Protagonist Therapeutics Inc.TAK· Takeda Pharmaceutical Company LimitedHealth Care
